Extended drotrecogin alfa (activated) treatment in patients with prolonged septic shock
β Scribed by Jean-Francois Dhainaut; Massimo Antonelli; Patrick Wright; Arnaud Desachy; Jean Reignier; Sylvain Lavoue; Julien Charpentier; Mark Belger; Michael Cobas-Meyer; Cornelia Maier; Mariano A. Mignini; Jonathan Janes
- Publisher
- Springer
- Year
- 2009
- Tongue
- English
- Weight
- 123 KB
- Volume
- 35
- Category
- Article
- ISSN
- 1432-1238
No coin nor oath required. For personal study only.
π SIMILAR VOLUMES
Recombinant human activated protein C (rhAPC) has been approved for use in patients with severe sepsis at high risk of death. Because of the high risk of bleeding, liver transplantation (LT) patients have been excluded from the randomized control trials that evaluated efficacy and safety of rhAPC an
Relative adrenal insufficiency is frequent in patients with severe sepsis and is associated with hemodynamic instability, renal failure, and increased mortality. This study prospectively evaluated the effects of steroids on shock resolution and hospital survival in a series of 25 consecutive patient